NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences. Details of the company’s participation are as follows: Citi’s 18th Annual BioPharma Conference Format: 1×1 Only Date: Thursday…


Previous articleClearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
Next articleOptimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program